This handout is for haemorrhoidal disease & common benign anorectal conditions (internal/external haemorrhoids goligher i–iv, thrombosed external haemorrhoid, acute anal fissure, perianal abscess pointer) — rectal bleeding not assumed benign. Your care team identified this based on: bright-red blood on stool / paper / dripping — not assumed haemorrhoidal until colorectal source excluded (siminoff 2015 pmid 26504796; ascrs 2024).
Other reasons your team may use this plan: perianal lump / prolapsing tissue with defecation (internal haemorrhoid grading) (ascrs 2024); acute severe perianal pain — thrombosed external haemorrhoid vs anal fissure vs perianal abscess pivot (greenspon 2004 pmid 15486746; ascrs 2023); pruritus ani / mucous discharge / soiling (haemorrhoidal symptom or alternative anorectal pathology) (ascrs 2024).
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| fibre_fluids_bowel_habit_modification | Increase dietary fibre + fluids; avoid straining/prolonged toilet sitting | dietary | continuous | ASCRS 2024 strong recommendation; Cochrane (Alonso-Coello CD004649 PMID 16235372) + meta-analysis (PMID 16405552) — fibre roughly halves risk of persistent symptoms/bleeding (RR ~0.50) |
| sitz_baths | Warm sitz bath 10–15 min, 2–3×/day esp. after defecation | topical | PRN/2-3x daily | ASCRS 2024/2023 — relieves sphincter spasm/discomfort; safe in pregnancy; adjunct for fissure and conservatively-managed thrombosed external haemorrhoid |
| psyllium | 3.4–7 g/day, titrate; with adequate fluid | PO | daily | ASCRS 2024 — soluble bulk fibre of choice; symptom/bleeding benefit (Alonso-Coello AJG 2006 PMID 16405552); pregnancy-safe |
| methylcellulose | 2 g PO 1–3×/day with water | PO | 1-3x daily | ASCRS 2024 — alternative bulk-forming fibre when psyllium poorly tolerated; same symptom benefit class |
| polyethylene glycol 3350 | 17 g in 240 mL water daily, titrate | PO | daily | ASCRS 2024 — osmotic laxative to soften stool and reduce straining when fibre alone insufficient; pregnancy-acceptable |
| lactulose | 15–30 mL PO daily, titrate | PO | daily | ASCRS 2024 — osmotic-laxative alternative; commonly used in pregnancy for constipation contributing to haemorrhoids |
| docusate | 100 mg PO BID | PO | BID | ASCRS 2024 — stool softener adjunct to reduce straining (modest evidence; used as adjunct not monotherapy) |
| acetaminophen | 500–1000 mg PO q6h (max 3 g/day) | PO | q6h PRN | ASCRS 2024 — preferred analgesic; pregnancy-safe first-line for anorectal pain |
| ibuprofen | 400 mg PO q6–8h PRN, short course | PO | q6-8h PRN | ASCRS 2024 — short-course NSAID for thrombosed-external/post-procedure pain; AVOID in pregnancy (esp. 3rd trimester) and GI-bleeding risk |
Plan: Haemorrhoid stepwise management — conservative → symptomatic topical/venotonic → procedural escalation (ASCRS 2024 + Cochrane fibre/laxatives/phlebotonics + Shanmugam/HubBLe/eTHoS/Greenspon)
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Recurrence counselling + sustained bowel-habit/fibre maintenance; CONFIRM age-appropriate colorectal cancer screening is completed/up to date (the safety close-out — never close a rectal-bleeding episode without it); pregnancy postpartum resolution counselling (most resolve); escalate non-responders to colorectal referral; route IBD (gi.crohns.core.v1), portal-HTN/varices (gi.cirrhosis.core.v1), or malignancy as identified (ASCRS 2024/2023)
Guideline: ASCRS 2024 Clinical Practice Guidelines for the Management of Hemorrhoids (Hawkins, Dis Colon Rectum 2024) + ASCRS 2023 Clinical Practice Guidelines for the Management of Anal Fissures (Davids, Dis Colon Rectum 2023) + ACG/ESCP + Cochrane (fibre/laxatives, RBL vs haemorrhoidectomy, phlebotonics, non-surgical anal fissure)